Stay updated with breaking news from Andy Plump. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Christopher O’Reilly: Thank you very much for joining FY 2022 earnings announcement of Takeda. I will serve as MC, Head of IR. My name is O’Reilly.
Takeda Pharmaceutical drug TAK-279 achieved the main goal of a mid-stage clinical trial in plaque psoriasis, setting the stage for Phase 3. The Japanese pharmaceutical giant sees the small molecule as complementary to its top-selling product, the blockbuster inflammatory bowel disorder drug Entyvio, and competitive against Bristol Myers Squibb's Sotyktu.
Christopher O'Reilly: Thank you for taking time out of your very busy schedule to join us for the FY 22 Q3 Earnings Announcement by Takeda. My name is O'Reilly, Head of IR.